Six-Year EVOLUT LOW RISK Data Shows Higher Reintervention Rates for TAVR vs Surgery in Low-Risk Aortic Stenosis Patients

Six years after undergoing either surgery or transcatheter aortic valve replacement (TAVR (搜索)搜索该药品) with self-expanding valves, low-risk patients with aortic stenosis (搜索)搜索该疾病 experienced no significant differences in terms of all-cause mortality or disabling stroke, according to new findings from the EVOLUT LOW RISK trial published in JACC. However, the data revealed concerning trends in reintervention rates that may influence treatment decisions for younger, low-risk patients.

Key Findings Show Durability Concerns

The latest follow-up analysis from John K. Forrest, MD, FACC, and Steven J. Yakubov, MD, FACC, found the composite endpoint of all-cause mortality or disabling stroke was 23.3% among those assigned to TAVR (搜索)搜索该药品 versus 20.4% among those assigned to surgery at the six-year mark. While this difference was not statistically significant, reintervention rates told a different story.

Reintervention rates varied significantly between the two groups starting at year six, with 5.5% in the TAVR (搜索)搜索该药品 cohort requiring reintervention compared with 3.3% in the surgery cohort. The researchers performed additional analysis of available seven-year data, which indicated further increases in the incidence of reintervention among those in the TAVR group (9.8%) versus surgery (6%).

Aortic Regurgitation Drives Higher Reintervention Rates

The analysis revealed that aortic regurgitation (搜索)搜索该疾病 was the primary driver of higher reintervention rates in TAVR (搜索)搜索该药品 patients. When broken down by indication, the rate of reintervention for regurgitation was 5.6% in the TAVR group compared with 1.6% in the surgery group. For stenosis, the rates were more comparable at 3.6% versus 3.5%, respectively.

The researchers identified TAVR (搜索)搜索该药品 and valve model as predictive factors for reintervention and emphasized that the study "highlights the critical importance of transparent, robust, long-term clinical and real-world data in low-surgical-risk patients undergoing TAVR."

Expert Commentary Emphasizes Measured Interpretation

In a related editorial, Ziad A. Ali, MD, DPhil, cautioned that while the findings "are real, clinically relevant and deserving of wide dissemination," the interpretation must remain proportional to what the data can reliably support. He noted that "as transcatheter valve therapy continues to evolve, these data remind us that durability is multifaceted, that failure phenotypes may vary by platform and anatomy, and that procedural decisions made at the time of implant may have consequences that unfold years later."

Post-Dilation Technique Impact on Valve Performance

A separate study published in JACC: Cardiovascular Interventions examined the effects of different post-dilation strategies on Evolut THV (搜索)搜索该药品 leaflets. When post-dilation was performed according to Instructions For Use (IFU) recommendations, the valve frame geometry was preserved with no leaflet damage. However, when performed using larger than IFU-recommended balloon sizes, post-dilation resulted in outward over-expansion and a spectrum of leaflet damage ranging from microscopic to complete tears.

Implications for Clinical Practice

Aakriti Gupta, MD, MS, FACC, and David J. Cohen, MD, MSc, highlighted several key insights from the findings, including the importance of long-term follow-up, the critical role of heart team-based discussions with patients that transparently address both known benefits and remaining uncertainties, and recognition that "reintervention is an imperfect surrogate for valve performance."

The researchers noted that while the seven-year data was incomplete, they felt it important to publish at this time to "support heart teams and patients in navigating a shared decision-making process."

Future Surveillance and Follow-up

Looking ahead, yearly follow-up of EVOLUT LOW RISK trial participants is planned through 10 years to continue monitoring and comparing mortality rates, structural valve deterioration, and reintervention rates. JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, and Sanket S. Dhruva, MD, MHS, FACC, emphasized the need to move beyond passive post-market surveillance to infrastructure that "prioritizes automatic, timely, and complete longitudinal follow-up as a core responsibility of device-based care."

The findings come at a time when the field is expanding TAVR (搜索)搜索该药品 indications to include asymptomatic patients, making long-term durability data increasingly critical for informed decision-making in younger, lower-risk populations.